Will Nestle (NSRGY) Stock Be Affected By $1.4 Billion Skin Care Deal?

NEW YORK (TheStreet) -- Looking to extend its skin care unit, Nestle (NSRGY) will pay $1.4 billion in cash for the right to sell products made by Valeant Pharmaceuticals (VRX), Bloomberg reported.

The Switzerland-based holding company for the Nestle Group is looking to purchase the facial aesthetic treatments Restylane, Perlane, and Emervel to sell in the U.S. and Canada. The company already sells those products outside of North America.

Nestle is looking to build up a strong skin-care unit as its main food business struggles, Bloomberg noted.

Must ReadWarren Buffett's 25 Favorite Stocks 

NSRGY Chart NSRGY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries